Proteomics in diabetic nephropathy

Hyun Jung Kim, Hyun Syuk Yoo, Chan Wha Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40% of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.

Original languageEnglish
Pages (from-to)301-311
Number of pages11
JournalProteomics - Clinical Applications
Volume2
Issue number3
DOIs
Publication statusPublished - 2008 Mar 1

Fingerprint

Diabetic Nephropathies
Proteomics
Medical problems
Biomarkers
Proteome
Diabetes Complications
Chronic Kidney Failure
Diabetes Mellitus
Technology

Keywords

  • 2-D PAGE
  • Biomarker
  • Protein marker discovery

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Proteomics in diabetic nephropathy. / Kim, Hyun Jung; Yoo, Hyun Syuk; Kim, Chan Wha.

In: Proteomics - Clinical Applications, Vol. 2, No. 3, 01.03.2008, p. 301-311.

Research output: Contribution to journalArticle

Kim, Hyun Jung ; Yoo, Hyun Syuk ; Kim, Chan Wha. / Proteomics in diabetic nephropathy. In: Proteomics - Clinical Applications. 2008 ; Vol. 2, No. 3. pp. 301-311.
@article{ddb7e240567941fc8bc92a6c6e820f0e,
title = "Proteomics in diabetic nephropathy",
abstract = "Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40{\%} of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.",
keywords = "2-D PAGE, Biomarker, Protein marker discovery",
author = "Kim, {Hyun Jung} and Yoo, {Hyun Syuk} and Kim, {Chan Wha}",
year = "2008",
month = "3",
day = "1",
doi = "10.1002/prca.200780062",
language = "English",
volume = "2",
pages = "301--311",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "3",

}

TY - JOUR

T1 - Proteomics in diabetic nephropathy

AU - Kim, Hyun Jung

AU - Yoo, Hyun Syuk

AU - Kim, Chan Wha

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40% of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.

AB - Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40% of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.

KW - 2-D PAGE

KW - Biomarker

KW - Protein marker discovery

UR - http://www.scopus.com/inward/record.url?scp=41149088788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149088788&partnerID=8YFLogxK

U2 - 10.1002/prca.200780062

DO - 10.1002/prca.200780062

M3 - Article

C2 - 21136835

AN - SCOPUS:41149088788

VL - 2

SP - 301

EP - 311

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 3

ER -